PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robert Hofmeister et al.

Serial No.: 10/580,660

Filed: May 26, 2006

For: COMPOSITIONS COMPRISING POLYPEPTIDES Group Art Unit: 1643

Examiner: Unknown

Atty. Dkt. No.: DEBE:066US

Confirmation No.: 1727

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: October 30, 2006

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filling of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:066US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectably submitted,

Steven L. Highlander Reg. No. 37,642 Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date: October 30, 2006

								Page 1 of 2
Form PTO-1449 (modified)				Atty. Docket No.		Ser	ial No.	
			DEBE:066US		10/	\$80,660		
List of Patents and Publications for Applicant's			Applicant Robert Hofmeister et al.					
INFORMATION DISCLOSURE STATEMENT				Robert Holmeiste	r et al.			
				Filing Date:		Gre	up:	
	(Use so	everal sheets if necessary)		May 26, 2006		164		
				atent Documents Other Art				
See Page 1			Sı	See Page 1 See Page 1-2			1-2	
				nt Document				
Exam.	Ref.	Document Number	Date	Name	9	lass	Sub Class	Filing Date
Init,	Des.	Number	-				Class	of App.
	Foreign Patent Documents							
Exam. init.	Ref. Des.	Document Number	Date	Country		Language		
	B1	EP 1348715	11/19/03	Europe	English			
	B2	WO 99/54440	10/28/99		English			
		WO 33134440	10/20/99	WIPO			English	
_		Art (Including	1		ertine	nt Pa		Etc.)
Exam. Init.			1		ertine	nt Pa		Etc.)
Exam.	Other /		Author,	Title, Date P Citation the Dimer to Monore	er Transit		ages, I	
Exam.	Ref. Des.	Art (Including	Author, s Influencing to Biochemistry CCR5-expresement of ch	Title, Date P Citation the Dimer to Monore, 37:12918-12926, issing cells with bisper	er Transit 998. cific antil	tion of	ages, I	dy Single-
Exam.	Ref. Des.	Art (Including Arndt et al., "Factor Chain Fv Fragment," Bruhl, "Depletion of new strategy in the t	Author, s Influencing to Biochemistry CCR5-expresentment of ch. I. ial Killing of	Title, Date P Citation the Dimer to Monom r, 37:12918-12926, i ssing cells with bispuronic inflammatory	er Transli 1998. scific antil diseases a	nd HIV	ages, I	dy Single- skine toxins: a mol.,
Exam.	Ref. Des. C1	Ardt (Including Arndt et al., "Factor Chain Fv Fragment, Bruhl, "Depletion of new strategy in the 166:2420-2426, 200 Hoffman et al., "Ser (CD3-bispecific sing	Author, Influencing (Biochemistry CCR5-expresentment of ch.) Influencing (CCR5-expresentment of ch.) Influencing (CCR5-expresentment of ch.)	Title, Date P Citation the Dimer to Monom the Dimer	er Transit 998. scific antil diseases a exic T cell national.	oodies and HIV	ages, I an Antiboo and chemo and chemo coted with I of Cancer ant asciter	dy Single- skine toxins: a mol., a CD19- r, 115:98-104,
Exam.	Ref. Des. C1 C2 C3	Ard (Including Arndt et al., "Factor Chain Fv Fragment, Bruhl, "Depletion of new strategy in the 166:2420-2426, 200 Hoffman et al., "Ser (CD3-bispecific sing 2005. Jager et al., "Immun	Author, Influencing to Biochemistry CCR5-expresentment of chila Isla Killing of the chain antibute emonitoring to trifunctional High-level ex	Title, Date P Citation the Dimer to Monom y, 37:12918-12926, issing cells with bisperonic inflammatory namor cells by cytotocyl construct," Inter- tof tumor cell elimina bispecific antibodie pression in insect cell	er Transit 998. ecific antil diseases a xic T cell mational. tion from "Eur. J.	bodies : nd HIV s redire Journa maligr Cance	ages, I an Antibo and chemo and chemo and chemo and chemo and chemo and accided with I of Cance ant ascite r, 37:860, n of secret	dy Single- skine toxins: a mol., a CD19- r, 115:98-104, s during 2001.
Exam.	Ref. Des. C1 C2 C3	Art (Including Arndt et al., "Factor Chain Fv Fragment, Bruhl, "Depletion of new strategy in the 166;2420-2426, 200 Hoffman et al., "Ser (/CD3-bispecific sing 2005. Jager et al., "Immun immunotherapy with Kretzschmar et al.,"	Author, Influencing to Biochemistry CCR5-expretereatment of ch. I. Ida Killing of the Influencian antibute the monitoring of trifunctional High-level excodies," J of Museution and biot trithcrapy of in the propy of the property of the pr	Title, Date P Citation the Dimer to Monom s, 37:12918-12926, is sing cells with bisperonic inflammatory numor cells by cytoto doly construct," Inter- of fumor cell elimina bispecific antibodies prasion in insect cell mnumo logical Methological Methological activity of a	er Transit 998. scific antil diseases a xic T cell national. tion from ," Eur. J. s and purieds, 195:9	bodies and HIV s redire maligr Canos ification 3-101, ant bisp	an Antibourand chemone, "J Imms betted with and active mant asciter, 37:S60, an of secret 1996.	dy Single- skine toxins: a mol., a CD19- r, 115:98-104, s during 2001. ed monomeric gle-chain
Exam.	Ref. Des. C1 C2 C3 C4 C5	Art (Including Amdi et al., "Factor Chain Fv Fragment, Bruhl, "Depletion of new strategy in the 166:2420-2426, 200 Hoffman et al., "See "ACD3-bispecific sing 2005. Jage et al., "Immun immunotherapy with Kretzschmar et al.," a single-chain Fv and Kufer et al., "Constantibody designed fix	Author, s Influencing to Biochemistry CCR5-expreserement of ch. laid Killing of the chain antible le-chain antible le-chai	Title, Date P Citation the Dimer to Monom, 37:12918-12926, 18-1292	er Transit 998. ceific antil diseases a xic T cell mational, tion from " Eur. J. s and puri ds, 195:9 recombin rectal can	maligrama maligr	ages, I an Antiboo and cheme T," J Imms acted with I of Cance ant ascite T, 37:S60, n of secret 1996. accific sinj ancer Imm Tr Single-	ty Single- tikine toxins: a mol., a CD19- r, 115:98-104, s during 2001. ed monomeric gle-chain nsmol.

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEPSO9; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT,

EXAMINER:

			Page 2 of 2
Form PTO-1449 (modified)	Atty. Docket No.	Serial No.	
	DEBE:066US	10/580,660	
List of Patents and Publications for Applicant's	Applicant		
	Robert Hofmeister et al.		
INFORMATION DISCLOSURE STATEMENT			

(Use several sheets if necessar	y) May 26, 2006	Group: 1643
U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	See Page 1	See Page 1-2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
C8		Loeffler et al., "Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct," Leukemia, 17:900-909, 2003.
	C9	Loffler et al., "A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoms-directed cytotoxicity by unstimulated T lymphocytes," Blood, 95:2098-2103, 2000.
	C10	Luellau et al., "Development of a downstream process for the isolation and seperation of monoclonal immunoglobulin A monomers, dimers and polymers from cell culture supernatant," J. Chromatography, 796:162-175, 1998.
	C11	Mack et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity," PNAS 92:7021-7025, 1995.
	C12	Mack et al., "Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity," J Immunol., 15:3965-3970, 1997.
	C13	Maletz et al., "Bispecific Single-Chain Antibodies as Effective Tools for Eliminating Epithelial Cancer Cells From Human Stem Cell Preparations by Redirected Cell Cytotoxicity," International Journal of Caneer, 93:409-416, 2001.
	C14	Schoberth et al., "A New Class of Trifunctional Bispecific Antibodies Mediated Efficient Immunological Purging of Peripberal Blood Stem Cells," Eur. J. Cancer, 37:S51, 2001.
	C15	Worn et al., "Stability Engineering of Antibody Single-Chain Fv Fragments," J Mol Biology, 305:989-1010, 2001.

25711007.1

EXAMINER: DATE CONSIDERED:

EXAMENER: INITIAL IF REPERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN COMPORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FRAM WITH NEXT COMMUNICATION TO APPLICANT